This biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity
Fennec Pharmaceuticals is a not big biotechnology company aimed at the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.
Nowadays, STS is being studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity.
Fennec Pharma PO Box 13628 68 TW Alexander Drive Research Triangle Park,